SCHEDULE: FMR LLC Discloses 9.5% Stake in Roivant Sciences

Sentiment:

Beneficial Ownership Report 5 February 2026 1:36 PM

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 9.5% beneficial ownership stake in Roivant Sciences Ltd. as of December 31, 2025.

Summary

FMR LLC and Abigail P. Johnson reported beneficial ownership of 65,779,463.77 shares of Roivant Sciences Ltd. common stock.
This represents 9.5% of the total outstanding common stock of Roivant Sciences Ltd.
The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.
FMR LLC holds sole voting power over 65,714,345.00 shares and sole dispositive power over 65,779,463.77 shares.
Abigail P. Johnson, as a control person of FMR LLC, is also deemed to beneficially own the same aggregate amount of shares with sole dispositive power.
The filing was made under Rule 13d-1(b), classifying FMR LLC as a parent holding company or control person.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a major institutional investor like FMR LLC maintaining a substantial 9.5% stake in Roivant Sciences Ltd. suggests continued confidence and strategic interest in the company.

Positives

A significant institutional investor, FMR LLC (Fidelity), maintaining a 9.5% stake in Roivant Sciences Ltd. indicates continued confidence or strategic interest in the company.
The disclosure of a substantial holding by a major financial institution can be viewed positively by the market, suggesting a thorough due diligence process and belief in the company's long-term prospects.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Roivant Sciences Ltd.'s future performance or strategic direction, as it is solely a disclosure of beneficial ownership.

Management Comments

The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that the continued significant stake by FMR LLC, a major institutional asset manager, in Roivant Sciences Ltd. suggests ongoing institutional interest in the biotechnology or pharmaceutical sector, particularly in companies with innovative pipelines or strategic positioning. Such a substantial holding by a reputable firm like Fidelity can often be seen as a vote of confidence, potentially attracting further investor attention to Roivant Sciences and its peers.

Comparison to Industry Standards

A 9.5% beneficial ownership stake by a single institutional entity like FMR LLC is a substantial position, often placing them among the top shareholders.
For a biotechnology or pharmaceutical company like Roivant Sciences, attracting and retaining large institutional investors is a common indicator of perceived value and growth potential, aligning with industry benchmarks for well-regarded firms.
While specific comparable companies are not mentioned in the filing, such a stake is comparable to significant institutional holdings seen in other mid-to-large cap biotech firms where major asset managers often take positions to gain exposure to specific therapeutic areas or innovative platforms.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Shareholder Voting Agreement	Members of the Johnson family, including Abigail P. Johnson, who are predominant owners of Series B voting common shares of FMR LLC (representing 49% of voting power), have entered into a shareholders' voting agreement. This agreement dictates that all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940.	NA	This agreement centralizes voting power within the Johnson family group for FMR LLC, which indirectly influences the investment decisions made by FMR LLC and its subsidiaries regarding their holdings, including the stake in Roivant Sciences Ltd.

Stakeholder Impact

Shareholders: The disclosure of a significant institutional holding by FMR LLC may increase investor confidence and potentially attract more institutional and retail investment, positively impacting share price stability and liquidity.
Company Management: A large, active institutional shareholder like FMR LLC may exert influence on corporate strategy and governance, potentially leading to increased scrutiny or alignment with long-term value creation.

Key Dates

Date	Description
2023-01-03	Effective date of Power of Attorney for FMR LLC signatory Stephanie J. Brown.
2023-01-10	Date of Schedule 13G filing by FMR LLC, accession number -23-000003, referenced for Power of Attorney.
2023-01-26	Effective date of Power of Attorney for Abigail P. Johnson signatory Stephanie J. Brown.
2023-01-31	Date of Schedule 13G filing by FMR LLC, accession number -23-000038, referenced for Power of Attorney.
2025-12-31	Date of event which requires filing of this statement (reporting period end date).
2026-02-04	Date of signing of the Schedule 13G Amendment No. 2.

Recommendation

hold

The filing indicates a significant and stable institutional holding by FMR LLC in Roivant Sciences Ltd. This suggests a long-term investment perspective from a major player, which is generally a positive signal. However, as a Schedule 13G filing, it does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. The existing large stake supports a 'hold' position for investors who believe in Roivant's long-term prospects, aligning with the institutional confidence shown.

Keywords

Roivant Sciences, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Fidelity

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.